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Abstract 
Introduction: We assessed the impact of surgical volume on peri-
operative outcomes and complications of robotic extended pelvic 
lymph node dissection (ePLND). 
Methods: From November 2008 to October 2012, a total of 233 
consecutive patients with intermediate- or high-risk clinically local-
ized prostate cancer underwent robot-assisted radical prostatectomy 
(RARP) and ePLND by a single, experienced open and laparoscopic 
surgeon. Data were prospectively collected. Complications were 
classified according to the Modified Clavien System. Complications 
potentially related to ePLND were documented. The minimum 
follow-up was 3 months. To evaluate the impact of surgical vol-
ume on the results, 4 patient subgroups (subgroup 1: cases 1–59; 
2: 60–117; 3: 118–175; 4: 176–233) were compared using the 
Chi-squared and Kruskal-Wallis tests.
Results: The mean (range) operative time for ePLND was 79 min-
utes (range: 48–144), with a steady performance over time 
(p = 0.784). The count of resected lymph nodes plateaued after 
60 procedures (mean [range]: 13 [range: 6–32], 15 [range: 7–34], 
17 [range: 8–41], 16 [range: 8–42] in Groups 1 to 4, respectively, 
p = 0.001). Tumour lymph node involvement was 12% in Groups 
1 and 2, 7% in Group 3 and 9% in Group 4 (p = 0.075). Overall, 
115 complications were reported in 98/233 patients (42%), with 
a significant decrease after 175 cases (p = 0.028). In Group 4, 3 
patients reported an ePLND-related bleeding requiring open revi-
sion. Lymphoceles were detected in 10/233 patients (4.2%) and 
1 patient (1.7%) in each of the Groups 2 to 4 required a percuta-
neous drainage. 
Conclusions: A surgeon with extensive experience is expected to 
achieve a safe learning curve for ePLND during RARP. A learning 
curve of 60 cases is suggested for optimal lymph node yield. 
Introduction 
Pelvic lymph node dissection (PLND) is the most effective 
method to detect lymph node metastases in prostate cancer 
patients undergoing radical prostatectomy.1 PLND provides 
appropriate staging and prognostic information to guide 
postsurgical follow-up and therapy.1 In addition, PLND has 
been shown to be curative, or at least beneficial, in patients 
with limited lymph node metastases.2-5 Concerning the sur-
gical approach, a recent systematic review of the literature 
clearly demonstrated that the PLND during robot-assisted 
radical prostatectomy(RARP) can be performed effectively 
and safely, providing similar outcomes compared to pure 
laparoscopic and open procedures.6-9
Moreover, several factors, including prior experience in 
open and/or laparoscopic surgery, type of training and sur-
gical volume, may affect the results of PLND. On the other 
hand, learning curve may differ from surgeon to surgeon and 
may depend on patient characteristics. Overall, there is no 
definitive consensus about the caseload needed to achieve 
proficiency for PLND, and the lack of appropriate standardi-
zation in assessing the learning curve makes comparisons 
between series difficult and inaccurate.10
In the present study, we systematically evaluated the 
impact of surgical volume on efficacy and safety profiles of 
extended PLND (ePLND) at the time of RARP in a single-
surgeon series. 
Methods 
Study cohort 
We prospectively collected clinical and pathological data 
from 233 consecutive patients undergoing RARP and ePLND 
(encompassing obturator, internal iliac, external iliac and 
common iliac nodes up to ureteral crossing) for interme-
diate- or high-risk clinically localized prostate cancer at 
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our institution from November 2008 to October 2012. All 
patients in the learning curve were included, and all pro-
cedures were performed by a single, experienced open and 
laparoscopic surgeon (AM). Patients underwent digital rectal 
examination, serum prostatic-specific antigen measurement, 
10 to 12 biopsies for cancer detection and staging by com-
puted tomography scans of the abdomen-pelvis and bone 
scan preoperatively. All patients provided written informed 
consent. Clinical parameters were assessed. 
In patients under antiplatelet/anticoagulant therapy, 
the therapy was discontinued 10 days before surgery. All 
patients received 2 g of cefazolin before surgery as a single-
shot antibiotic prophylaxis and subcutaneous low molecular 
weight heparin in the upper arm once daily from the day of 
admission to the day of discharge. 
The ePLND was performed in a standardized manner, 
as previously described.11 The operative time for ePLND 
was registered. The histologic investigation began with fat 
dissolution using an alcohol solution. The identified lym-
phatic structures and single nodes were fixed in paraffin and 
sectioned through the point of maximal diameter. Routinely, 
hematoxylin-eosin stain was used. In patients with unclear 
findings, an additional immunohistochemistry using pancy-
tokeratin was performed. 
Complications were classified according to the Modified 
Clavien System (Table 1).12 In particular, ePLND-related com-
plications (obturator nerve injury, bleeding, ureteral injury, 
deep venous thrombosis, pulmonary embolism, lymphocele) 
were documented. All patients underwent sonographic fol-
low-up to identify lymphoceles on postoperative days 5 and 
10, as well as at 3 and 12 months after surgery. All patients 
had a minimum of 3 months postoperative follow-up.
Statistical analysis 
To evaluate the impact of the single-surgeon learning curve 
on the results, patients were divided into 4 subgroups (sub-
group 1: cases 1–59; 2: cases 60–117; 3: cases 118–175; 4: 
cases 176–233). Data analysis was performed using the Chi-
squared and Kruskal-Wallis tests. Multivariate tests relied 
on logistic regressions and mixed linear regression models 
using STATA 12.1 (StataCorp, College Station, TX). Statistical 
significance was set at p ≤ 0.05. 
Results 
Baseline demographic characteristics are listed in Table 2. 
There was a statistically significant difference among the 
groups with respect to age (Groups 1 and 3 vs. Groups 2 
and 4; p = 0.015 for all). Additionally, in Group 4, a higher 
percentage of patients were under antiplatelet/anticoagulant 
therapy before surgery than in Groups 1 to 3 (p = 0.014). 
Surgical and pathological data are reported in Table 3. 
The mean (range) operative time for ePLND was 79 minutes 
(range: 48–144), and the procedure duration did not signifi-
cantly decrease with increasing surgical volume (p = 0.784) 
(Fig. 1). A significantly higher number of resected lymph 
nodes were found after 60 procedures (mean [range]: 13 
[6–32], 15 [7–34], 17 [8–41], 16 [8–42] in Groups 1, 2, 3 
and 4, respectively; Group 1 vs. Groups 2-4: p = 0.001). 
Table 1. Modified Clavien classification of surgical 
complications
Grade Definition
I
Any deviation from the normal postoperative course 
without the need for pharmacologic/surgical/radiological 
intervention
II Complication requiring pharmacologic treatment
III Requiring surgical/endoscopic/radiological intervention
IIIA Intervention without general anesthesia
IIIB Intervention under general anesthesia
IV
Life-threatening complication requiring intensive care 
unit management
IVA Single organ dysfunction
IVB Multiorgan dysfunction
V Patient mortality
Table 2. Baseline demographic characteristics
Overall Group 1 Group 2 Group 3 Group 4 p value
N 233
59
cases (1–59)
58
cases (60–117)
58
cases (118–175)
58
cases (176–233)
Age, years, mean (range) 64 (46–76) 63 (46–73) 66 (53–76) 63 (49–74) 65 (53–73) 0.015
BMI (kg/m2), mean (range) 27 (19–43) 26 (20–39) 26 (19–40) 27 (20–43) 27 (22–35) 0.431
CCI score, n. (%)
≤1
2
3
≥4
44 (19)
112 (48)
51 (22)
26 (11)
13 (22)
33 (56)
9 (15)
4 (7)
11 (19)
28 (49)
13 (22)
6 (10)
16 (27)
21 (36)
12 (21)
9 (16)
4 (7)
30 (52)
17 (29)
7 (12)
0.108
Antiplatelet/anticoagulant therapy 
before surgery, n (%) 53 (23) 8 (14) 8 (14) 17 (29) 20 (34) 0.014
PSA, ng/mL, mean (range) 7.7 (0.8–69) 8.2 (1.2–58.4) 8.1 (2.0–69) 6.5 (0.8–69) 9.3 (0.9–42.9) 0.069
Lorem ipsum PSA: prostate-specific antigen; BMI: body mass index; CCI: Charlson Comorbidity Index.
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In total, 115 complications were reported in 98/233 
patients (42%), with a significant decrease after 175 cases 
(p = 0.028) (Table 4). Minor complications represented the 
most frequent events (86/115 complications; 75%) and were 
still significantly reduced in Group 4 compared to Groups 
1 to 3 (p = 0.011). Specifically, ePLND-related complica-
tions were observed in 5%, 9%, 12% and 10% of patients 
in Groups 1, 2, 3 and 4, respectively (p = 0.087) (Table 5). 
Among the 21 ePLND-related complications in 21 
patients (9%), minor complications were the most frequent 
(14/21; 67%), showing a statistically significant improve-
ment in Group 4 (p = 0.031). Lymphoceles represented the 
most common events (10/21 ePLND-related complications; 
47%). They were detected in 10/233 patients (4%). Of note, 
only 1 patient (1.7%) in each of Groups 2 to 4 developed 
a symptomatic lymphocele requiring treatment by percu-
taneous drainage. Symptoms due to lymphoceles included 
infection/fever (Groups 2 and 3) and pelvic pain (Group 4). 
There was no difference between the right and left ePLND 
with respect to the occurrence of complications (p = 0.542). 
Discussion 
In prostate cancer patients treated with radical prostatec-
tomy, PLND is considered the most accurate method to 
determine lymph node status, with a potential therapeutic 
role by removing metastases.1-5 However, both surgeon- and 
patient-related factors may affect the outcomes of PLND. In 
particular, surgical experience plays a crucial role.13
To date, several methodological limitations remain when 
evaluating the learning curve for urological procedures, 
including PLND.10 The most relevant gap is the absence of 
a shared definition of learning curve and of standardized 
methods to assess outcomes. Overall, despite the increasing 
number of trials focusing on robotic surgery,10 there is little 
data on the impact of surgical volume on the efficacy and 
safety profiles of ePLND during RARP.
Defining a surgeon’s caseload for achieving proficiency in 
a new technique is important. To help define this caseload, 
we analysed the learning curve for robotic ePLND in prostate 
cancer patients. To the best of our knowledge, this is the 
first study to prospectively evaluate the association between 
surgical volume and results for ePLND in RARP using stand-
ardized criteria in a single-surgeon series. In fact, any novel 
approach presents a distinct learning curve for each indi-
vidual surgeon that differs from the learning curve calculated 
by analyzing a group of surgeons. 
When operative time was used as the outcome variable, 
the length of surgery did not significantly improve as the sur-
gical volume increased (Table 3). Of note, the longest time 
(144 minutes) occurred in Group 3, whereas the shortest 
(48 minutes) in Group 4 (Fig. 1). The absence of a decrease 
in the ePLND time may indicate the performance of more 
challenging cases, which are taken on with increased surgeon 
competence. Indeed, stratifying patients based on risk features 
proved to be statistically significant, with higher risk cases 
undergoing ePLND from Group 1 to Group 4 (p < 0.001). 
On the other hand, the ePLND time cannot be very short 
provided the template is being properly dissected bilaterally.11
In contrast, the time for RARP plus ePLND showed a pro-
gressive decrease with an increase in the surgeon’s experi-
ence (p = 0.001) (Table 3, Fig. 1). On the whole, this finding 
could imply the existence of a shorter time-related learning 
curve for RARP than for ePLND. 
Table 3. Surgical and pathological data
Overall Group 1 Group 2 Group 3 Group 4 p value
N 233
59
cases (1–59)
58
cases (60–117)
58
cases (118–175)
58
cases (176–233)
Operative time for RARP + ePLND, 
minutes, mean (range) 264 (150–475) 320 (200–475) 255 (150–465) 250 (165–400) 240 (169–400) 0.001
Operative time for ePLND, 
minutes, mean (range) 79 (48–144) 71 (52–132) 92 (70–130) 77 (49–144) 76 (48–120) 0.784
Attempted nerve sparing, n (%)  
All  
Monolateral
Bilateral
161 (69)
95 (41)
66 (28)
42 (71)
23 (39)
19 (32)
50 (86)
37 (64)
13 (22)
38 (65)
17 (29)
21 (36)
31 (53)
18 (31)
13 (22)
0.034
Pathological stadium, n (%)
T2
T3
T4
175 (75)
56 (24)
2 (1)
50 (85)
8 (13)
1 (2)
41 (71)
16 (27)
1 (2)
46 (79)
12 (21)
—
38 (66)
20 (34)
—
0.063
Dissected lymph nodes, n,  
mean (range) 15 (6–42) 13 (6–32) 15 (7–34) 17 (8–41) 16 (8–42) 0.001
Positive lymph nodes, n (%) 23 (10) 7 (12) 7 (12) 4 (7) 5 (9) 0.075
Positive margins, n (%) 44 (19) 13 (22) 9 (15) 10 (17) 12 (21) 0.485
RARP: robot-assisted radical prostatectomy; ePLND: extended pelvic lymph node dissection
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van der Poel and colleagues studied 440 cases treated 
with ePLND during RARP, in 7 of these cases the console 
time improved during the first 150 procedures and remained 
stable thereafter. The number of removed nodes increased 
from a median 10 (interquartile range [IQR]: 5–30) in the 
initial 50 cases to a median of 18 (IQR: 6–22) in case num-
bers 351 to 400. However, they included ePLND procedures 
performed by 2 surgeons, and such cases did not equally 
contribute to the series (number of ePLND = 363 vs. n = 77). 
In the present series of patients treated by a single 
surgeon, a mean of 15 (range: 6–42) lymph nodes were 
removed, with a significantly higher count occurring after 
60 procedures (p = 0.001). Considering that our patients 
underwent extended PLND, the count of resected nodes 
may appear low when compared to other series reporting 
on ePLND.8,9,14 However, it must be noted that the number 
and positivity of the dissected lymph nodes depend on the 
extent of PLND (as well as individual features of the patient 
and cancer), and these variables can also be influenced by 
pathological examination due to inter-institutional differ-
ences in lymphatic tissue dissection, collection and patho-
logical processing procedures as recently demonstrated by 
Meijer and colleagues.15 Several contiguous lymph nodes, 
for example, may be counted as a single node in some histo-
logical institutes and as more than one in others. Moreover, 
a large study of PLND for bladder cancer found that if lymph 
nodes are resected and analyzed en block, rather than as 
several separate tissue fragments, there is (1) no difference 
in the overall incidence of lymph node-positive disease 
and (2) a significant decrease of the total number of nodes 
counted, even though the same template was used.16-18 This 
is probably also true for ePLND in cases of prostate cancer, 
but no data are available. This could also help explain the 
difference in lymph node yield between our robot-assisted 
monoblock technique and the open approach or similar 
mini-invasive approaches not using a monoblock technique. 
On the other hand, adherence to the anatomic boundaries 
of the ePLND template is likely more important than the 
number of removed nodes, which depends on various fac-
tors that often are not controlled.19 
Conversely, the number of nodal metastases did not 
increase with accumulating experience (Table 3). In this 
context, as mentioned above, other variables, such as patho-
logic evaluation, may contribute to the detection of lymph 
node invasion. In addition, our percentage of positive lymph 
nodes (10%) may appear low. However, according to a 
recent literature review by Ploussard and colleagues,6 our 
positivity rate was within the ranges (0–22%) reported in 
other series. 
A potential pathologic bias is not applicable to our study 
because all of the specimens were analyzed by a single 
institution using a standardized procedure.
Fig. 1. Length of surgery for robot-assisted radical prostatectomy plus extended pelvic lymph node dissection 
(ePLND) and ePLND only over the learning curve.
CUAJ • March-April 2015 • Volume 9, Issues 3-4 111
efficacy of ePlnD at rarP
Overall, ePLND provides an advantage in terms of cancer 
cure in selected patients.2-5 This benefit, however, must be 
weighed against potential complications. 
According to the Modified Clavien System, we identi-
fied ePLND-related complications in 21/233 patients (9%) 
(Table 5). Lymphoceles represented the most common 
events (10/21 ePLND-related complications; 47%). In par-
ticular, as already demonstrated,20-22 the learning curve for 
RARP with ePLND is safe also at the beginning of experi-
ence and only a limited number (3/10; 30%) of lymphoceles 
were symptomatic and required treatment by percutaneous 
drainage. Also, in 4 (2%) patients we observed an obtura-
tor nerve deficit, with a full functional recovery during the 
follow-up. Although the number of neural injuries may seem 
unusual, this figure can be explained by the strict follow-up 
we carried on. In fact, we aimed to actively identify every 
single ePLND-related complication postoperatively. On the 
other hand, in other series these adverse events are likely 
not to be reported at all. 
On the whole, our incidence of ePLND-related com-
plications fell within the range reported by similar studies 
(3%–12%).7-9,23,24 In addition, it must be noted that we 
included all patients in the learning curve and reported any 
deviation from the intra- and postoperative standard course 
Table 4. Overall intra- and postoperative complications*
Overall Group 1 Group 2 Group 3 Group 4 p value
N 233
59
cases (1–59)
58
cases (60–117)
58
cases (118–175)
58
cases (176–233)
Total 115 in 98 patients (42%) 31 in 27 patients (46%) 32 in 29 patients (50%)
34 in 26 patients 
(45%)
18 in 16 patients 
(27%)
0.028
MINOR 86 in 77 patients (33%) 22 in 20 patients (34%) 25 in 23 patients (40%)
28 in 24 patients 
(41%)
11 in 10 patients 
(17%)
I
55 in 49 patients (21%)
Pressure skin redness (47)
Lymphocele (7)
Sciatic nerve deficit (1)
17 in 16 patients (27%)
Pressure skin redness 
(14)
Lymphocele (2)
Sciatic nerve deficit (1)
17 in 16 patients 
(28%)
Pressure skin redness 
(14)
Lymphocele (3)
18 in 14 patients 
(29%)
Pressure skin 
redness (16)
Lymphocele (2)
3 in 3 patients 
(5%)
Pressure skin 
redness (3)
0.011
II
31 in 26 patients (11%)
UTI (11)
Pressure skin ulcer (6)
Obturator nerve deficit (4)
Transfusion (3)
Humeral nerve deficit (1)
Femoralis nerve deficit (1)
Addison crisis (1)
Sciatic nerve  deficit (1)
Paralytic ileus (1)
Malignant hyperthermia (1)
Vein thrombosis (1)
5 in 4 patients (7%)
Femoralis nerve deficit 
(1)
Addison crisis (1)
Transfusion (1)
UTI** (1)
Pressure skin ulcer (1)
8 in 6 patients (10%)
Pressure skin ulcer 
(3)
UTI** (2)
Paralytic ileus (1)
Malignant 
hyperthermia (1)
Vein thrombosis (1)
10 in 9 patients 
(16%)
UTI** (5)
Obturator nerve 
deficit (3)
Humeral nerve 
deficit (1)
Pressure skin 
redness (1)
8 in 7 patients 
(12%)
UTI** (3)
Transfusion (2)
Pressure skin 
redness (1)
Sciatic nerve 
deficit (1)
Obturator nerve 
deficit (1)
MAJOR 29 in 25 patients (11%) 9 in 9 patients (15%) 7 in 7 patients (12%) 6 in 3 patients (5%)
7 in 6 patients 
(10%)
IIIa
19 in 15 patients (6%)
Urinary retention (6)
Pressure skin ulcer (3)
Lymphocele (3)
Anastomosis stricture (2)
Bladder tamponade (2)
Postop. hydronephrosis (1)
Ureteral injury (1)
Myocardial infarction (1)
7 in 7 patients (12%)
Pressure skin ulcer (3)
Anastomosis stricture 
(2)
Urinary retention (1)
Postop. 
hydronephrosis (1)
6 in 5 patients (10%)
Urinary retention (3)
Ureteral injury (1)
Bladder tamponade 
(1)
Lymphocele (1)
2 in 2 patients (3%)
Urinary retention 
(1)
Lymphocele (1)
4 in 3 patients 
(5%)
Bladder 
tamponade (1)
Urinary retention 
(1)
Lymphocele (1)
Myocardial 
infarction (1)
0.375
IIIb
8 in 8 patients (4%)
Postoperative bleeding (4)
Ureteral injury (1)
Port hernia (1)
Rectovesical fistula (1)
Anastomosis stricture (1)
2 in 2 patients (3%)
Ureteral injury (1)
Port hernia (1)
1 in 1 patients (2%)
Rectovesical fistula 
(1)
2 in 2 patients (3%)
Postoperative 
bleeding (1)
Anastomosis 
stricture (1)
3 in 3 patients 
(5%)
Postoperative 
bleeding (3)
IV
2 in 2 patients (1%)
Urinary sepsis (2)
— —
2 in 2 patients (4%)
Urinary sepsis (2)
—
V — — — — —
*See Table 5 for a listing of the Clavien grades. UTI: urinary tract infection. 
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as complications (including clinically insignificant events, 
such as asymptomatic lymphoceles not requiring therapy). 
Without considering those occurrences, our complication 
rate would drop to 6% (14 adverse events in 14/233 patients). 
Not surprisingly, the ePLND-related complication rate did 
not significantly decrease over time (Table 5). In fact, after 
the first 60 cases (5% of patients experienced complications), 
the complication rate skyrocketed to 9% in Group 2 and 
to 12% in Group 3, whereas it decreased to 10% in Group 
4 (p = 0.087). Groups 3 and 4 (the latter half of learning 
curve) were associated with a higher percentage of major 
complications compared to Groups 1 and 2 (3.4% and 7% 
vs. 0% and 1.7%; p = 0.015), indicating an apparent worsen-
ing of the surgeons’ performance. In particular, the highest 
rate of bleeding complications occurred in the latest Group 
(Table 5) and was associated with the introduction of a new 
patient-side surgeon. 
For these reasons, as suggested by the trend toward high-
er risk cases undergoing ePLND from Group 1 to Group 
4 (p < 0.001), more complex cases are being performed 
over time. In addition, an increasing number of patients 
on antiplatelet/anticoagulant therapy prior to surgery were 
observed in the last two Groups (p = 0.014). These find-
ings are confirmed by the gradually lowered percentage 
of nerve-sparing procedures and no significant decrease in 
positive surgical margin rates due to the inclusion of higher 
risk cases over time. 
This study has its limitations. The specific intraopera-
tive estimated blood loss for ePLND was not available. Our 
ePLND technique did not provide the exact anatomic loca-
tion of possible metastatic nodes. Long-term follow-up is 
required to draw definitive oncological conclusions. One 
of the major strengths of this study is that all of the proce-
dures were performed by a single surgeon in a consecutive 
series. This stipulation prevents variability in the outcomes 
due to including a group of surgeons with different surgical 
training levels and proficiencies. Therefore, we believe that 
the results of this study could assist and guide trainers and 
trainees when introducing ePLND for prostate cancer in 
similar clinical settings. 
Conclusion 
Defining the learning curve for any given procedure is 
required to improve outcomes and to reduce complications 
when introducing a surgical training program. Our study 
suggests that a surgeon with extensive open and laparo-
scopic experience can be expected to demonstrate a safe 
learning curve for ePLND at the time of RARP. A learning 
curve of 60 procedures is suggested for lymph node yield. 
However, long-term follow-up is required to draw definitive 
oncological conclusions.
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